KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Goodwill & Intangibles (2016 - 2025)

Teva Pharmaceutical Industries' Goodwill & Intangibles history spans 17 years, with the latest figure at $19.8 billion for Q4 2025.

  • For the quarter ending Q4 2025, Goodwill & Intangibles rose 1.1% year-over-year to $19.8 billion, compared with a TTM value of $19.8 billion through Dec 2025, up 1.1%, and an annual FY2025 reading of $19.8 billion, up 1.1% over the prior year.
  • Goodwill & Intangibles for Q4 2025 was $19.8 billion at Teva Pharmaceutical Industries, down from $19.9 billion in the prior quarter.
  • The five-year high for Goodwill & Intangibles was $28.7 billion in Q1 2021, with the low at $7.0 billion in Q2 2022.
  • Average Goodwill & Intangibles over 5 years is $22.4 billion, with a median of $22.5 billion recorded in 2023.
  • Year-over-year, Goodwill & Intangibles crashed 75.59% in 2022 and then skyrocketed 228.11% in 2023.
  • Tracing TEVA's Goodwill & Intangibles over 5 years: stood at $25.1 billion in 2021, then dropped by 6.58% to $23.4 billion in 2022, then fell by 3.77% to $22.6 billion in 2023, then fell by 13.29% to $19.6 billion in 2024, then grew by 1.1% to $19.8 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Goodwill & Intangibles are $19.8 billion (Q4 2025), $19.9 billion (Q3 2025), and $20.1 billion (Q2 2025).